SCHEMBL3478152

SCHEMBL3478152

CCCCCOC=N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25837889 0.97 THRB (0.42)
SCHEMBL3281363 0.97
SCHEMBL3280767 0.92
SCHEMBL27615968 0.77 THRB (0.38)
SCHEMBL6178131 0.77 THRB (0.41)
SCHEMBL16994989 0.77 THRB (0.41)
SCHEMBL14724824 0.74 ADRB2 (0.41)
SCHEMBL6178964 0.74 THRB (0.47)
SCHEMBL65046 0.74
SCHEMBL17416222 0.72 THRB (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215764-A Preparation method of deuterated aromatic nitrile compound 浙大宁波理工学院 2022-10-21 CN disclosed
CN-115215764-A Preparation method of deuterated aromatic nitrile compound 浙大宁波理工学院 2022-10-21 CN disclosed
US-7863250-B2 An immunostimulatory oligonucleotide having the structure 5'-TCTGTC1GTTCT-X-TCTTGC1TGTCT-5'; wherein X is a glycerol linker and C1 is 1-(2'-deoxy- beta -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine; cancer, an autoimmune disorder, airway inflammation, asthma, allergy IDERA PHARMACEUTICALS, INC. (US) 2011-01-04 US disclosed
WO-2010146449-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF IMIPENAM ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) 2010-12-23 WO disclosed
US-7851453-B2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides IDERA PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed
US-20100254974-A1 Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends IDERA PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-7595305-B2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides IDERA PHARMACEUTICALS (US) 2009-09-29 US disclosed